Understanding Adenylate Cyclase 3 (ADCY3) and Its Role in Obesity

ADCY3, a transmembrane enzyme located in the cilia of primary neurons, is a key genetic candidate. The ADCY3 gene is located on chromosome 2p23.3 and consists of 21 exons. Variations in this gene are associated with a predisposition to obesity, particularly affecting appetite control, energy expenditure, and fat storage. Identifying mutations and changes in the ADCY3 gene provides key insights into the genetic basis of obesity and provides a reference for developing personalized treatment plans. At Protheragen, we provide professional Obesity Causation Analysis Services such as Genetically Induced Obesity Causation Analysis, Disease-Induced Obesity Causation Analysis, and Medication-Induced Obesity Causation Analysis. ADCY3 is one of the genetically induced obesity analysis services, and we use a comprehensive set of analytical tests to detect and understand genetic variants and mutations associated with obesity.

We use cutting-edge research and bioinformatics tools to pinpoint pathways and proteins that play key roles in obesity and metabolic regulation and then help clients develop anti-obesity therapies against specific targets.

We design and conduct rigorous preclinical studies utilizing advanced in vitro and in vivo obesity models to evaluate the efficacy and safety of these therapeutics. Our preclinical studies are carefully planned to provide insightful data on pharmacokinetics, toxicity, and therapeutic potential.

Unlocking Genetic Insights, Exploring Obesity Mechanisms: ADCY3 Gene Analysis Service

Protheragen uses a range of advanced bioanalytical technologies to accurately detect and analyze genetic changes of ADCY3 gene in Obesity Models. These technologies include next-generation sequencing (NGS) for genetic analysis, quantitative polymerase chain reaction (qPCR) for accurate quantification of gene expression, etc. By integrating these cutting-edge methods, Protheragen ensures a comprehensive and accurate understanding of the role of this gene and its changes in the context of obesity research, thereby facilitating the development of targeted therapeutic interventions.

• Genetic Sequencing

  We analyze genomic DNA to identify ADCY3 gene mutations, variations, or alterations that may be associated with obesity. We extract DNA from samples and prepare sequencing libraries to ensure accurate detection of genetic changes. We then use NGS technology to comprehensively cover and map the ADCY3 gene at high resolution. It accurately mappes the complete sequence of the ADCY3 gene and identifies the smallest genetic variations including single nucleotide polymorphisms (SNPs) and insertions/deletions. We combine bioinformatics tools and software to analyze sequencing data and pinpoint specific mutations that may cause or contribute to the obesity phenotype.

• PCR and Real-time PCR

  We use PCR to amplify and analyze specific DNA fragments in ADCY3 gene-induced obesity animal models to detect ADCY3 gene mutations or variations that may cause obesity. This analysis method performs targeted analysis of known mutation sites with high sensitivity and specificity, thereby understanding the genetic mechanism of obesity driven by the ADCY3 gene.

• Gene Expression Analysis

  qPCR and RNA sequencing are used to accurately measure ADCY3 mRNA levels in various tissue samples. This approach accurately quantifies and compares gene expression, providing valuable insights into the molecular mechanisms behind the obese phenotype. The data obtained help to map changes in ADCY3 expression and correlate them with obesity-related traits in animal models.

• Protein Analysis

  Our protein analysis is to reveal genetic changes in obesity at the protein level by comparing ADCY3 protein expression, localization, and function in obese and non-obese animal models to identify changes that may contribute to the obese phenotype. Our methods are as follows:

  • Western blotting and enzyme-linked immunosorbent assay (ELISA) to quantify protein levels and activity
  • Immunohistochemistry (IHC) to visualize protein distribution within tissues
  • Co-immunoprecipitation (Co-IP) to study protein-protein interactions

Workflow

Applications

• In-depth gene expression analysis to evaluate the differential expression pattern of ADCY3 gene and identify new biomarkers of obesity.
• Analyze the downstream effects of ADCY3 gene regulation to understand the cellular and physiological processes related to ADCY3 expression changes and energy balance, appetite regulation, and fat metabolism.
• Study the mechanism by which ADCY3 affects obesity such as signaling pathways, protein-protein interactions, and other molecular events that are altered in the case of ADCY3 dysfunction.

Advantages

• We combine cutting-edge technologies with deep expertise in genetics and obesity research to provide clients with comprehensive and accurate ADCY3 gene testing services. Our technologies include but are not limited to qPCR, NGS, IHC, Co-IP, etc.
• Dual evaluation of ADCY3-induced obesity models at both gene expression and protein levels ensures a thorough understanding of the genetic impact on ADCY3 obesity development.
• Tailor-made solutions to meet clients' specific needs. Whether the focus is on identifying obesity-related phenotypes, understanding molecular mechanisms, or studying therapeutic targets, Protheragen customizes the optimal analysis solution to suit the research goals.

Publication Data

Frequently Asked Questions

What tissue samples are collected for analysis?

Tissue samples commonly collected include adipose tissue (white and brown fat), liver, and muscle tissue, which play key roles in metabolism, energy homeostasis, and obesity regulatory mechanisms. Adipose tissue is essential for studying fat storage and metabolism. The liver is used to examine glycogen storage, insulin sensitivity, and lipid metabolism. Muscle tissue is used to analyze energy expenditure and glucose absorption. These tissue samples undergo rigorous molecular analysis to determine the expression levels of ADCY3 and related metabolic genes.

What kind of animal models are used in this analysis?

We use various animal models to analyze the obesity mechanism induced by the ADCY3 gene, such as the dog obesity model, pig obesity model, mouse obesity model, rat obesity model, monkey obesity model, guinea pig obesity model, rabbit obesity model, etc.

Protheragen uses the most advanced technology to test the changes in the ADCY3 gene in samples, aiming to thoroughly understand the mechanism of obesity and provide obese patients with solutions tailored to their genetic characteristics. Please feel free to contact us to combine precision medicine with unparalleled expertise to explore the future of obesity management.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.